<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment; Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment; Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2018-02-16 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled "Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment." The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of X-linked Duchenne muscular dystrophy (DMD) and related dystrophinopathies. This guidance finalizes the draft guidance of the same name issued on June 10, 2015.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2018-03225</p>
    <p><strong>Publication Date:</strong> 2018-02-16</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2018/02/16/2018-03225/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-for-treatment-guidance">https://www.federalregister.gov/documents/2018/02/16/2018-03225/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-for-treatment-guidance</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2018-03225</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
